We connect doctors and patients, partners and public health care institutions.
We see ourselves as bridge builders.
What we want is to lastingly improve the lives of our patients
- We offer a broad and modern product portfolio particularly for the indications cardiovascular diseases, respiratory diseases, and diabetes.
- We seek to help doctors improve the lives of as many patients as possible, protecting patients as best possible against the serious consequences of their diseases.
- We make research results available in all their various aspects, whether these come in the form of new treatments or as scientific findings on already established drugs that have been confirmed in current guidelines.
- We seek new product partnerships – to achieve the greatest possible added value for our patients.
Our goal is to implement successful research so it benefits our patients
OUR VISION & OUR VALUES
I wholeheartedly dedicate myself to the welfare of our patients. My work is entirely devoted to doing the utmost to ease the lives of those living with a serious disease as best possible. I am joined in this task by my colleagues and by working in partnership with doctors and their teams.
Our sales experience in pharmaceutical drugs still known today, such as the first ACE inhibitor captopril (Tensobon), the third proton pump inhibitor pantoprazole (Rifun), the second AT1 blocker (Provas), and the first asthma fixed combination fluticasone/salmeterol (Atmadisc), helped us continuously expand our offering.
Today our portfolio includes drugs which benefit a great number of patients receiving treatment in primary health care practices. This particularly applies to the single-pill treatment principle in the indication fields of cardiovascular diseases but also to drugs administered in the fields of respiratory diseases and diabetes mellitus. More
Here at a glance you can see who is in charge of what at APONTIS PHARMA.
Karlheinz GastCEOactive in the industry since 1986 and holding the following company positions since 1997:General Manager BU Internal Medicine (UCB Pharma GmbH)Senior Director BU Internal Medicine (UCB Pharma GmbH)Sales Director (Schwarz Pharma Deutschland GmbH)
Thomas MilzDirector of Strategic Business Development & Market Accessactive in the industry since 1991 and holding the following company positions from 1991 to 1996 and since 1997:Director Market Access (UCB Pharma GmbH)Director Marketing (Schwarz Pharma Deutschland GmbH)Product Manager & Head of Marketing Vascular (Schwarz Pharma Deutschland GmbH)
Dr. med. Matthias WendlHead of Salesactive in the industry since 2002 and holding the following company positions from 2002 to 2006 and since 2011:Head of Sales North Germany (UCB Pharma GmbH)
Associate Director Strategic Projects (UCB Pharma GmbH)
Product & Medical Manager (Schwarz Pharma Deutschland GmbH)
Harald WeyandHead of Marketingactive in the industry since 1989 and holding the following company positions since 1989:Associate Director Marketing (UCB Pharma GmbH)Health Politics & Patient Access (Schwarz Pharma Deutschland GmbH)Head of Marketing Vascular (Schwarz Pharma Deutschland GmbH)Group Product Manager Sanol GmbH (Schwarz Pharma Deutschland GmbH)Market Research (Schwarz Pharma Deutschland GmbH)
Dr. med. Olaf RanderathHead of Medical Affairsactive in the industry since 1998 and holding the following company positions from 1998 to 2009 and since 2011:Head of CNS New Products Medical Affairs (UCB Pharma GmbH)
Head of Development Projects Medical Affairs (UCB Pharma GmbH)
Head of Clinical Development (Schwarz Pharma Deutschland GmbH)
Associate Medical Director (UCB Pharma GmbH)
Dr. Susanne EndreßHead of QA, Drug Safety & Regulatory Affairsactive in the industry since 1995 and holding the following company positions since 1998:Head of Drug Safety and Local Qualified Person for Pharmacovigilance (UCB GmbH)
Head of Regulatory Affairs & Quality Assurance (UCB GmbH / UCB Pharma GmbH)
What is our focus? Expansion of our product portfolio and product pipeline
Until 2006, the company was owned by the families SCHWARZ and SCHWARZ-Schütte, after which it was acquired by the Belgian corporation UCB. As UCB Internal Medicine, the field of Primary Care was for many years a mainstay of the corporation’s German business. However, the UCB corporation focused ever more intensively on the therapeutic areas Neurology and Immunology, leaving Internal Medicine to increasingly develop into an independent unit. Which it did with great success.
In October 2018, the unit was acquired by the private, owner-managed investor Paragon Partners. This successfully achieved change of ownership means an investor has come aboard whose great interest in a long-term cooperation ensures the continuity of our collaboration with doctors and the expansion of our product portfolio.